+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Total Artificial Heart - Medical Devices Pipeline Assessment, 2019

  • ID: 4898181
  • Report
  • December 2019
  • Region: Global
  • 68 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abiomed Inc
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart Inc
  • ReliantHeart, Inc.
  • Syncardia Systems LLC
  • MORE
Total Artificial Heart - Medical Devices Pipeline Assessment, 2019

Summary

The Medical Devices sector report, “Total Artificial Heart - Medical Devices Pipeline Assessment, 2019“ provides an overview of Total Artificial Heart currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by the team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Total Artificial Heart under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Total Artificial Heart under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abiomed Inc
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Heart Inc
  • ReliantHeart, Inc.
  • Syncardia Systems LLC
  • MORE
1 Introduction
1.1 Total Artificial Heart Overview

2 Products under Development
2.1 Total Artificial Heart - Pipeline Products by Stage of Development
2.2 Total Artificial Heart - Pipeline Products by Territory
2.3 Total Artificial Heart - Pipeline Products by Regulatory Path
2.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date
2.5 Total Artificial Heart - Ongoing Clinical Trials

3 Total Artificial Heart - Pipeline Products under Development by Companies
3.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development
3.2 Total Artificial Heart - Pipeline Products by Stage of Development

4 Total Artificial Heart Companies and Product Overview
4.1 Abiomed Inc Company Overview
4.1.1 Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
4.2 BiVacor Pty Ltd Company Overview
4.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
4.3 Carmat SAS Company Overview
4.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
4.4 Cleveland Clinic Lerner College of Medicine Company Overview
4.4.1 Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
4.5 Cleveland Heart Inc Company Overview
4.5.1 Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
4.6 Foster-Miller Inc (Inactive) Company Overview
4.6.1 Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
4.7 Indian Institute of Technology Kharagpur Company Overview
4.7.1 Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
4.8 Lausanne University Hospital Company Overview
4.8.1 Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview
4.9 OregonHeart Inc (Inactive) Company Overview
4.9.1 OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
4.10 ReliantHeart, Inc. Company Overview
4.10.1 ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
4.11 Scandinavian Real Heart AB Company Overview
4.11.1 Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
4.12 Syncardia Systems LLC Company Overview
4.12.1 Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
4.13 TEDA International Cardiovascular Hospital Company Overview
4.13.1 TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
4.14 University of Tokyo Company Overview
4.14.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
4.15 Yale University Company Overview
4.15.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview

5 Total Artificial Heart- Recent Developments
5.1 Nov 27, 2019: CARMAT appoints Alexandre Eleonore as director of manufacturing
5.2 Nov 19, 2019: CARMAT granted authorization to resume the PIVOTAL study in the Czech Republic
5.3 Nov 13, 2019: Micron Solutions reports 2019 third quarter results
5.4 Nov 06, 2019: CARMAT: the feedback after 6 years and 8 months of cumulative support shows a constant improvement in the clinical outcomes of patients in the PIVOTAL study
5.5 Oct 31, 2019: Abiomed announces Q2 FY 2020 revenue of $205 million and 29.4% operating margin

6 Appendix
6.1 Methodology
6.2 About the Author
6.3 Contact Us
6.4 Disclaimer

List of Tables
Table 1: Total Artificial Heart - Pipeline Products by Stage of Development
Table 2: Total Artificial Heart - Pipeline Products by Territory
Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Table 5: Total Artificial Heart - Ongoing Clinical Trials
Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development
Table 7: Total Artificial Heart - Pipeline Products by Stage of Development
Table 8: Abiomed Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: AbioCor II - Product Status
Table 10: AbioCor II - Product Description
Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 12: BiVACOR Device - Product Status
Table 13: BiVACOR Device - Product Description
Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 15: Artificial Heart - Product Status
Table 16: Artificial Heart - Product Description
Table 17: Carmat SAS - Ongoing Clinical Trials Overview
Table 18: Artificial Heart - Carmat Total Artificial Heart Early Feasibility Study
Table 19: Artificial Heart - Clinical Evaluation of the Carmat Total Artificial Heart for Patients with Advanced Heart Failure
Table 20: Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Continuous-Flow Total Artificial Heart - Product Status
Table 22: Continuous-Flow Total Artificial Heart - Product Description
Table 23: Pediatric Continuous-Flow Total Artificial Heart - Product Status
Table 24: Pediatric Continuous-Flow Total Artificial Heart - Product Description
Table 25: Cleveland Heart Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 26: SmartHeart TAH - Product Status
Table 27: SmartHeart TAH - Product Description
Table 28: Foster-Miller Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 29: MagScrew Total Artificial Heart - Product Status
Table 30: MagScrew Total Artificial Heart - Product Description
Table 31: Indian Institute of Technology Kharagpur Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Artificial Heart - Product Status
Table 33: Artificial Heart - Product Description
Table 34: Lausanne University Hospital Pipeline Products & Ongoing Clinical Trials Overview
Table 35: RollingHeart - Product Status
Table 36: RollingHeart - Product Description
Table 37: OregonHeart Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Next Generation Total Artificial Heart - Product Status
Table 39: Next Generation Total Artificial Heart - Product Description
Table 40: ReliantHeart, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Pulse Less Total Artificial Heart - Product Status
Table 42: Pulse Less Total Artificial Heart - Product Description
Table 43: Scandinavian Real Heart AB Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Total Artificial Heart - Product Status
Table 45: Total Artificial Heart - Product Description
Table 46: Syncardia Systems LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 47: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Status
Table 48: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - Product Description
Table 49: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Status
Table 50: SynCardia 50cc Temporary Total Artificial Heart - Destination Therapy - Product Description
Table 51: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Status
Table 52: SynCardia 50cc Temporary Total Artificial Heart - Pediatric Bridge To Transplant - Product Description
Table 53: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Status
Table 54: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - Product Description
Table 55: Syncardia Systems LLC - Ongoing Clinical Trials Overview
Table 56: SynCardia 70cc Temporary Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)
Table 57: SynCardia 50cc Temporary Total Artificial Heart - Adult Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant
Table 58: TEDA International Cardiovascular Hospital Pipeline Products & Ongoing Clinical Trials Overview
Table 59: Artificial Heart - Product Status
Table 60: Artificial Heart - Product Description
Table 61: University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
Table 62: Helical Flow Total Artificial Heart - Product Status
Table 63: Helical Flow Total Artificial Heart - Product Description
Table 64: Yale University Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Corisma - Product Status
Table 66: Corisma - Product Description
Table 67: Glossary

List of Figures
Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development
Figure 2: Total Artificial Heart - Pipeline Products by Territory
Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Figure 5: Total Artificial Heart - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abiomed Inc
  • BiVacor Pty Ltd
  • Carmat SAS
  • Cleveland Clinic Lerner College of Medicine
  • Cleveland Heart Inc
  • Indian Institute of Technology Kharagpur
  • Lausanne University Hospital
  • ReliantHeart, Inc.
  • Scandinavian Real Heart AB
  • Syncardia Systems LLC
  • TEDA International Cardiovascular Hospital
  • University of Tokyo
  • Yale University
Note: Product cover images may vary from those shown
Adroll
adroll